A spatial transcriptomics study of MES-like and mono/macro cells in gliomas

Area of Science:

• Neuro-oncology
• Genomics
• Bioinformatics

Background:

• Gliomas, including glioblastoma multiforme (GBM) and lower-grade glioma (LGG), are challenging due to genetic diversity and poor prognosis.
• Identifying therapeutic targets and prognostic markers is crucial for improving patient outcomes.

Purpose of the Study:

• To perform a comprehensive multi-omics analysis of gliomas.
• To identify potential therapeutic targets and prognostic markers using bioinformatics approaches.

Main Methods:

• Analyzed 1327 sequencing data samples from TCGA, CCGA, and UCSC Xena datasets.
• Utilized gene expression profiling, survival analysis, spatial transcriptomics, and drug sensitivity analysis.
• Assessed immunotherapy response using the Tumor Immune Dysfunction and Exclusion (TIDE) framework.

Main Results:

• Mesenchymal (MES)-like malignant and monocyte/macrophage (mono/macro) cell subsets play significant roles in the glioma tumor microenvironment.
• MES-like malignant marker gene scores correlated with overall survival; mono/macro marker gene scores were significant in TCGA-LGG and CCGA datasets.
• Mono/macro cells showed better immunotherapy responsiveness (lower TIDE scores); spatial transcriptomics localized MES-like tumors and identified drug sensitivities.

Conclusions:

• Mesenchymal-like malignant and monocyte/macrophage cells have differential roles in glioma progression and immune modulation.
• These findings offer novel insights into glioma biology and potential therapeutic strategies.
• Identified key cell-cell interactions (e.g., CD14-ITGB2, LGALS1-CD69, APOE-TREM2) influencing tumor behavior.